1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. PMID:
20610543.
2. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416. PMID:
9537241.
3. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-1514. PMID:
16533775.
5. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 2011;25:433-441. PMID:
21165579.
6. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-4652. PMID:
16000556.
7. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 2011;137:1061-1070. PMID:
21207061.
8. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006;12(11 Pt 1):3337-3343. PMID:
16740755.
9. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kolosza Z, et al. Evaluation of selected serum protein markers as early detectors of ovarian cancer. Ginekol Pol 2008;79:271-275. PMID:
18592865.
10. Abu El, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol 2011;10:296-305. PMID:
21677331.
11. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26:4771-4776. PMID:
18779603.
12. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009;4:1104-1110. PMID:
19620934.
13. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010;28:936-941. PMID:
20085934.
14. Winum JY, Scozzafava A, Montero JL, Supuran CT. Inhibition of carbonic anhydrase IX: a new strategy against cancer. Anticancer Agents Med Chem 2009;9:693-702. PMID:
19601749.
15. Supuran CT, Briganti F, Tilli S, Chegwidden WR, Scozzafava A. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem 2001;9:703-714. PMID:
11310605.
16. Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004;10:7925-7933. PMID:
15585626.
17. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16:4853-4863. PMID:
20651059.
18. Hyrsl L, Zavada J, Zavadova Z, Kawaciuk I, Vesely S, Skapa P. Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. Neoplasma 2009;56:298-302. PMID:
19473055.
21. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. PMID:
17762336.
22. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-1126. PMID:
21718227.
23. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-830. PMID:
17168734.
24. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007;57:373-380. PMID:
17513004.
25. Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl Res 2012;159:343-353. PMID:
22424436.
26. Prasse A, Stahl M, Schulz G, Kayser G, Wang L, Ask K, et al. Essential role of osteopontin in smoking-related interstitial lung diseases. Am J Pathol 2009;174:1683-1691. PMID:
19359522.
27. Hillas G, Loukides S, Kostikas K, Simoes D, Petta V, Konstantellou E, et al. Increased levels of osteopontin in sputum supernatant of smoking asthmatics. Cytokine 2013;61:251-255. PMID:
23098767.